Novartis Oncology provides a full range of patient support services through Novartis Patient Assistance Now Oncology (PANO). A complete list of Novartis Oncology medications and their related assistance programs is provided in the Table.
Novartis PANO
Novartis PANO offers insurance benefit verification, information about financial assistance options, patient support counselors, patient navigators, and dedicated case managers who will assist patients in identifying which Novartis Oncology patient support programs they are eligible to receive, including the Novartis Oncology Universal Co-pay Program, free trial programs, and the Novartis Patient Assistance Foundation. To enroll, your patient will complete their portion of the PANO Service Request Form (SRF) online; once their portion is complete, the prescribing physician can complete their portion of the SRF. To learn more or to enroll your patient in PANO, please visit Novartis PANO.
Novartis also offers drug-specific programs for several medications, including Kisqali Care, Kymriah Cares, Promacta4U and Rydapt NOW.
The Novartis Patient Assistance Foundation (NPAF) provides assistance to uninsured and underinsured patients. Not all Novartis Oncology medicines are currently supported by NPAF.
Kisqali Care is a PANO program that can provide copay assistance, free trials of Kisqali, and other helpful information and resources. Patients can enroll in Kisqali Care by calling 800-282-7630 or visiting Kisqali Care.
Kymriah Cares
Kymriah Cares is a support program designed to help patients access Kymriah, including financial assistance, patient support programs, information about insurance coverage, and coordination of care support. To learn more, patients can call 844-459-6742 or visit Kymriah Cares.
TABLE Novartis Oncology/Supportive Care Drugs
Drugs
Indications
Patient support programs
Drug
Afinitor (everolimus) tablets/Afinitor Disperz (everolimus tablets for oral suspension)
Treatment of chronic iron overload due to blood transfusions in patients 2 years and older.
Treatment of chronic iron overload in patients 10 years and older with non-transfusion-dependent thalassemia syndromes, and with a liver iron (Fe) concentration of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L.
Treatment of chronic iron overload in patients 10 years and older with non-transfusion-dependent thalassemia syndromes and with a liver iron (Fe) concentration of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L
Treatment of adults with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor; postmenopausal adults with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or after disease progression on endocrine therapy, in combination with fulvestrant
Treatment, in combination with fulvestrant, of postmenopausal women, and men, with hormone receptor–positive, HER2-negative, advanced or metastatic breast cancer and PIK3CA mutation, as detected by an FDA-approved test, that is progressing during or after an endocrine-based regimen
Treatment of newly diagnosed adults with acute myeloid leukemia with FLT3 mutation, in combination with cytarabine and daunorubicin induction and high-dose cytarabine consolidation; aggressive systemic mastocytosis, systemic mastocytosis with hematologic neoplasm, or mast-cell leukemia in adults
Sandostatin LAR Depot (octreotide acetate for injectable suspension)
Indications
Treatment of severe diarrhea or flushing episodes in metastatic carcinoid; acromegaly; profuse watery diarrhea associated with vasoactive intestinal peptide–secreting tumors
Treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors; treatment of adult patients with Ph+ CML in CP with the T315I mutation
Treatment of metastatic non–small cell lung cancer in adult patients whose tumors have a mutation that leads to mesenchymal-epithelial transition exon 14 skipping, as detected by an FDA-approved test
Afinitor (everolimus) tablets/Afinitor Disperz (everolimus tablets for oral suspension) Indications
Treatment of postmenopausal women with advanced hormone receptor–positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole; adults with progressive neuroendocrine tumors of pancreatic origin and adults with progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin that are unresectable, locally advanced, or metastatic disease; adults with advanced renal-cell carcinoma after failure of treatment with sunitinib or sorafenib; adults with renal angiomyolipoma and tuberous sclerosis complex not requiring immediate surgery
Arzerra (ofatumumab)
Treatment of chronic lymphocytic leukemia (CLL):
in combination with chlorambucil, for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate
in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed CLL
for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL
for the treatment of patients with CLL refractory to fludarabine and alemtuzumab
Gleevec (imatinib mesylate) Indications
Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase; Ph+ CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy; relapsed or refractory Ph+ acute lymphoblastic leukemia (Ph+ ALL); newly diagnosed Ph+ ALL in combination with chemotherapy; myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangements; aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown; hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) in patients who have the FIP1L1-PDGFRα fusion kinase and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown; unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans; Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST); adjuvant treatment of adult patients following resection of Kit (CD117)-positive GIST
Hycamtin (topotecan hydrochloride) for injection Indications
Treatment of metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent; small-cell lung cancer platinum-sensitive disease that progressed at least 60 days after initiation of first-line chemotherapy, as a single agent; stage IV-B, recurrent, or persistent cervical cancer that is not amenable to curative treatment, in combination with cisplatin
Kymriah (tisagenlecleucel) Indications
Treatment of patients up to 25 years with relapsed or refractory B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse; adults with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (FL); adults with relapsed or refractory FL after 2 or more lines of systemic therapy
Mekinist (trametinib) Indications
Single agent in BRAF-inhibitor treatment-naive patients, or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test; in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection; in combination with dabrafenib, for the treatment of patients with metastatic non–small cell lung cancer with BRAF V600E mutation, as detected by an FDA-approved test; in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and no satisfactory locoregional treatment options; in combination with dabrafenib for the treatment of patients ≥1 year of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options; treatment of pediatric patients ≥1 year of age with low-grade glioma with a BRAF V600E mutation who require systemic therapy
Promacta (eltrombopag)
Treatment of:
thrombocytopenia in adult and pediatric patients ≥1 year with persistent or chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy;
thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy;
in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients ≥2 years with severe aplastic anemia;
patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy
Tafinlar (dabrafenib) Indications
Single agent in BRAF-inhibitor treatment-naive patients, or in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test; in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection; in combination with trametinib, for the treatment of patients with metastatic non–small cell lung cancer with BRAF V600E mutation, as detected by an FDA-approved test; in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and with no satisfactory locoregional treatment options; in combination with trametinib for the treatment of patients ≥1 year of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options; the treatment of pediatric patients ≥1 year of age with low-grade glioma with a BRAF V600E mutation who require systemic therapy
Tasigna (nilotinib) Indications
Treatment of adult and pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); treatment of adult patients with CP and accelerated phase Ph+ CML resistant or intolerant to prior therapy that included imatinib; treatment of pediatric patients ≥1 year of age with CP and accelerated phase Ph+ CML with resistance or intolerance to prior tyrosine kinase inhibitor therapy
Tykerb (lapatinib) Indications
In combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab; in combination with letrozole for the treatment of postmenopausal women with hormone receptor–positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated